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Prophylactic radiotherapy for the prevention of 
procedure-tract metastases after surgical and large-bore 
pleural procedures in malignant pleural mesothelioma 
(SMART): a multicentre, open-label, phase 3, randomised 
controlled trial
Amelia O Clive, Hazel Taylor, Lee Dobson, Paula Wilson, Emma de Winton, Niki Panakis, Justin Pepperell, Timothy Howell, Samuel A Stewart, 
Erika Penz, Nikki Jordan, Anna J Morley, Natalie Zahan-Evans, Sarah Smith, Timothy J P Batchelor, Adrian Marchbank, Lesley Bishop, 
Alina A Ionescu, Mike Bayne, Samantha Cooper, Anthony Kerry, Peter Jenkins, Elizabeth Toy, Vallipuram Vigneswaran, James Gildersleve, 
Merina Ahmed, Fiona McDonald, Mick Button, Conrad Lewanski, Charles Comins, Muthukumar Dakshinamoorthy, Y C Gary Lee, 
Najib M Rahman, Nick A Maskell
Summary
Background The use of prophylactic radiotherapy to prevent procedure-tract metastases (PTMs) in malignant pleural 
mesothelioma remains controversial, and clinical practice varies worldwide. We aimed to compare prophylactic 
radiotherapy with deferred radiotherapy (given only when a PTM developed) in a suitably powered trial.
Methods We did a multicentre, open-label, phase 3, randomised controlled trial in 22 UK hospitals of patients with 
histocytologically proven mesothelioma who had undergone large-bore pleural interventions in the 35 days prior to 
recruitment. Eligible patients were randomised (1:1), using a computer-generated sequence, to receive immediate 
radiotherapy (21 Gy in three fractions within 42 days of the pleural intervention) or deferred radiotherapy (same dose 
given within 35 days of PTM diagnosis). Randomisation was minimised by histological subtype, surgical versus 
non-surgical procedure, and pleural procedure (indwelling pleural catheter vs other). The primary outcome was the 
incidence of PTM within 7 cm of the site of pleural intervention within 12 months from randomisation, assessed in 
the intention-to-treat population. This trial is registered with ISRCTN, number ISRCTN72767336.
Findings Between Dec 23, 2011, and Aug 4, 2014, we randomised 203 patients to receive immediate radiotherapy 
(n=102) or deferred radiotherapy (n=101). The patients were well matched at baseline. No signiﬁ cant diﬀ erence was 
seen in PTM incidence in the immediate and deferred radiotherapy groups (nine [9%] vs 16 [16%]; odds ratio 0·51 
[95% CI 0·19–1·32]; p=0·14). The only serious adverse event related to a PTM or radiotherapy was development of a 
painful PTM within the radiotherapy ﬁ eld that required hospital admission for symptom control in one patient who 
received immediate radiotherapy. Common adverse events of immediate radiotherapy were skin toxicity (grade 1 in 
50 [54%] and grade 2 in four [4%] of 92 patients vs grade 1 in three [60%] and grade 2 in two [40%] of ﬁ ve patients in the 
deferred radiotherapy group who received radiotherapy for a PTM) and tiredness or lethargy (36 [39%] in the immediate 
radiotherapy group vs two [40%] in the deferred radiotherapy group) within 3 months of receiving radiotherapy. 
Interpretation Routine use of prophylactic radiotherapy in all patients with mesothelioma after large-bore thoracic 
interventions is not justiﬁ ed.
Funding Research for Patient Beneﬁ t Programme from the UK National Institute for Health Research.
Copyright © Clive et al. Open Access article distributed under the terms of CC BY.
Introduction
Malignant pleural mesothelioma is an aggressive 
tumour with a poor prognosis, and few treatment 
options are available. In 2012, 2535 mesothelioma deaths 
were reported in the UK alone, and the incidence is 
predicted to increase.1,2 Patients often have multiple 
diagnostic and therapeutic pleural interventions to 
conﬁ rm the diagnosis and manage symptomatic 
malignant pleural eﬀ usions. However, a complication of 
these procedures is that the tumour can spread to the 
site of previous interventions, resulting in procedure-
tract metastases (PTMs). Data from a retrospective 
study3 suggest that the risk of these potentially painful 
nodules developing increases with the size of the chest 
wall incision.
Mesothelioma is sensitive to radiation therapy in vitro,4 
but its use as a radical treatment is limited by the dose 
that can be delivered safely to thoracic organs at risk. 
Prophylactic radiotherapy to pleural intervention sites 
can be given with minimal side-eﬀ ects; however, results 
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from three small randomised controlled trials5–7 assessing 
its eﬃ  cacy in reducing PTMs are conﬂ icting and 
showed substantial variation in PTM incidence. 
Three meta-analyses8–10 of these data concluded that there 
was insuﬃ  cient evidence to recommend the use of 
prophylactic radiotherapy. Speciﬁ cally, there is a paucity 
of data regarding the incidence of clinically relevant, 
symptomatic nodules. These factors have resulted in 
variation in clinical practice8,11 worldwide and in 
international guidelines;12–17 therefore, a suitably powered 
randomised controlled trial is needed.
The SMART trial aimed to establish whether immediate 
radiotherapy given within 42 days of a large-bore pleural 
intervention reduces the incidence of PTMs developing 
in mesothelioma, compared with deferred radiotherapy 
delivered only when PTMs develop. Additionally, we 
aimed to assess the diﬀ erences in pain scores, analgesia 
requirements, quality of life, adverse events, and survival 
between the treatment groups.
Methods
Study design and participants
The SMART trial was a multicentre, open-label, phase 3 
randomised controlled trial that recruited consecutive 
patients from 22 hospitals in the UK (appendix). 
We recruited patients who had a histocytologically 
proven diagnosis of malignant pleural mesothelioma 
and had undergone (in the previous 35 days) an open 
pleural biopsy, surgical thoracotomy or video-assisted 
thoracoscopic surgery, local anaesthetic thoracoscopy, 
large-bore chest tube insertion (≥20 French [Fr] 
inserted by either a Seldinger technique or blunt 
dissection), or an indwelling pleural catheter insertion. 
The 35-day cutoﬀ  was extended from 28 days to improve 
patient recruitement after a protocol amendment 
accepted by the regional ethics committee on 
Aug 1, 2012.
Patients were ineligible if they were younger than 
18 years, had an expected survival of less than 4 months, 
were pregnant or lactating, were unable to give informed 
consent or comply with the protocol, had had previous 
radiotherapy resulting in an unacceptable overlap with 
the proposed treatment ﬁ eld, had no access to a telephone, 
or had a clinically palpable nodule of 1 cm or larger in 
diameter within 7 cm of the margins of the procedure site 
at the initial trial visit.
The trial was sponsored by North Bristol National 
Health Service (NHS) Trust and coordinated by the 
Respiratory Research Unit at North Bristol NHS Trust. 
The trial and subsequent protocol amendments were 
approved by the South Central (Southampton B) Ethics 
Committee of the UK National Research Ethics Service 
(REC: 11/SC/0408). There was no data monitoring 
committee for the trial. The full protocol18 was published 
before the completion of trial follow-up. All patients 
provided written informed consent before recruitment.
Randomisation and masking
We randomly assigned patients (1:1) to receive either 
immediate prophylactic radiotherapy (within 42 days of 
the pleural intervention) or deferred radiotherapy (given 
if the patient subsequently developed a PTM). Treatment 
allocation was done over the telephone by the Oxford 
Respiratory Trials Unit, operated by staﬀ  independent of 
the study. The randomisation sequence was generated 
with a validated, online randomisation service (Sealed 
Envelope, London, UK). Minimisation with a random 
component was used to reduce the baseline diﬀ erences 
between the two groups. The three minimisation factors 
were histological subtype of mesothelioma (epithelioid 
only vs other), pleural procedure (indwelling pleural 
catheter vs other), and nature of procedure (ie, open 
pleural biopsy, thoracotomy, or video-assisted thoraco-
scopic surgery vs non-surgical procedure).
Research in context
Evidence before this study
We searched MEDLINE, Embase, CINAHL, and AMED for 
articles published until Sept 16, 2015, that reported 
prophylactic radiotherapy in mesothelioma. We used the 
keywords “mesothelioma”, “neoplasms, mesothelial”, and 
“Prophylactic Radiotherap* OR irradiation OR radiation 
therapy”. We assessed titles, keywords, and abstracts, and 
obtained full texts of articles that we deemed relevant. 
We used the Critical Appraisal Skills Programme checklist to 
assess the quality of the evidence. We identiﬁ ed three 
published randomised controlled trials and one additional 
randomised controlled trial that is still in the follow-up 
period. We found three systematic reviews incorporating 
evidence from randomised trials and non-randomised 
studies; all three reviews concluded that there was insuﬃ  cient 
evidence to recommend prophylactic radiotherapy in 
mesothelioma and called for a large-scale randomised 
controlled trial to be done.
Added value of this study
Our results show that prophylactic radiotherapy to large-bore 
pleural intervention sites does not confer beneﬁ ts in terms of 
the rate of procedure-tract metastasis (PTM), chest pain, quality 
of life, analgesia use, or survival.
Implications of all the available evidence
Taken together with results from the three previous 
randomised controlled trials, prophylactic radiotherapy is 
ineﬀ ective in preventing PTMs in unselected patients with 
mesothelioma. Future studies should explore whether there is 
any beneﬁ t of this treatment in speciﬁ c patient subgroups—
eg, those not receiving chemotherapy and those with 
epithelioid-only tumour subtypes. 
For the full protocol see 
http://bmjopen.bmj.com/
content/5/1/e006673.full
See Online for appendix
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Patients and clinicians were not masked to treatment 
allocation; therefore, outcome assessments were 
unblinded. Data analysis was blinded from treatment 
allocation. The trial database was held at The Oxford 
Respiratory Trials Unit.
Procedures
Patients allocated to the immediate radiotherapy group 
received 21 Gy in three fractions over 3 working days, 
initiated within 42 days of the procedure for which the 
patient had been randomised. The target volume 
encompassed the chest drain, surgical sites or scars, 
and, in the case of indwelling pleural catheters, the 
whole of the catheter tract and skin exit site, with at 
least a 3 cm margin. The volume treated needed to have 
been acceptable to the treating clinical oncologist, and 
the treatment diameter and width needed to have been 
at least 7 cm. Further details of the radiotherapy 
protocol can be found in the published protocol.18 
The quality assurance programme for the trial is 
detailed in the appendix.
Patients in the deferred radiotherapy group received 
radiotherapy only if they were diagnosed with a PTM 
during trial follow-up. If a PTM was identiﬁ ed, patients 
received 21 Gy of radiotherapy in three fractions over 
3 working days, delivered within 35 days of PTM 
diagnosis. The target volume encompassed the nodule 
with at least a 2 cm margin, and the treatment volume 
needed to have been acceptable to the treating clinical 
oncologist.
All patients were followed up monthly until death or for 
12 months. Patients visited the hospital at randomisation 
and at 1, 3, 6, 9, and 12 months after randomisation. 
Each hospital visit included a focused history (detailing 
radiotherapy toxicity, mesothelioma treatments received, 
analgesia use, and health-care use) and a chest wall 
examination by two independent assessors to identify 
PTMs and radiation toxicity. Patients also completed 
quality-of-life questionnaires (European Organization for 
Research and Treatment of Cancer Quality-of-Life 
Questionnaire—Core 30 [QLQ-C30] and EuroQoL-5D 
[EQ-5D]), a visual analogue scale score (on a scale of 
0–100 mm, with no pain at 0 mm and worst possible pain 
at 100 mm) for chest pain, and questionnaires about their 
experience of radiotherapy or the development of a PTM 
(if applicable). In the months that patients were not seen 
in person (ie, months 2, 4, 5, 7, 8, 10, and 11), they instead 
received a telephone call from a research nurse to enquire 
about symptoms at the intervention site. They also 
completed a chest pain visual analogue scale score. 
If problems were identiﬁ ed during a telephone 
consultation, a clinic appointment was arranged.
Patients recruited at Bristol and Oxford were oﬀ ered 
the opportunity to discuss their experience of the trial in 
a semi-structured, qualitative interview 6 months after 
trial entry.18 Common themes from analysis of these 
interviews will be identiﬁ ed and reported separately. 
Patients were removed from the study only if they 
withdrew consent for ongoing trial follow-up.
Outcomes
The primary endpoint was the incidence of PTM within 
12 months from randomisation within the intention-to-
treat population. A PTM was deﬁ ned as a clinically 
palpable nodule of at least 1 cm in diameter that was 
within 7 cm of the margins of the pleural intervention site, 
as conﬁ rmed by two independent assessors (including at 
least one doctor who made a clinical diagnosis of tract 
metastasis). Disagreement was resolved by consensus. 
For patients who died or were lost to follow-up, their last 
known outcome was used for the analysis.
The predeﬁ ned secondary outcomes were a per-
protocol analysis of the primary outcome (excluding 
patients with major protocol violations); summary chest 
pain visual analogue scale scores from randomisation to 
12 months after randomisation; summary quality-of-life 
score (as measured by QLQ-C30 and EQ-5D) from 
randomisation to 12 months after randomisation; 
analgesia requirements; the size, symptom severity, and 
time to development of PTM; incidence and severity of 
radiotherapy toxicity (according to the Radiation Therapy 
Oncology Group [RTOG] grading system19); the number 
of serious adverse events related to radiotherapy or a 
PTM; overall survival in days from randomisation to 
death; the health economics of immediate and deferred 
radiotherapy; and the identiﬁ cation of emergent themes 
pertaining to patient experience from the semi-structured 
interviews. 
Statistical analysis
The sample size calculation was based on internal audit 
data from our regional mesothelioma multidisciplinary 
team (unpublished data) of PTM rates in those 
undergoing large-bore procedures and the published 
literature that was available at the time of the grant 
application. Assuming a PTM incidence of 2% in the 
immediate radiotherapy group and 15% in the delayed 
radiotherapy group, 185 patients were required to show a 
diﬀ erence between treatment groups with 90% power 
(two-sided p=0·05), allowing for a 3% loss to follow-up. 
Results from various power modelling scenarios showed 
that the recruitment of 203 patients would allow 
adequate power with varied control and intervention 
event rates.18 The study was powered to address the 
primary outcome only, and not the secondary endpoints. 
The full analysis plan was published before any data 
assessment or database lock.18
We analysed the primary outcome in the intention-to-
treat population, using a Fisher’s exact test to compare 
PTM incidence between the treatment groups. We did 
several predeﬁ ned subgroup analyses for the primary 
outcome, including analyses split by type of pleural 
intervention, histological subtype, survival to 6 months, 
and receipt of chemotherapy.18 In our secondary, 
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predeﬁ ned, per-protocol analysis, we included only 
patients with no major protocol violations, deﬁ ned as 
failure to give immediate radiotherapy to those 
randomised to this treatment group, failure to meet the 
eligibility criteria for the study, or a major violation to 
the immediate radiotherapy protocol—speciﬁ cally, 
giving less than 21 Gy in three fractions, giving 
radiotherapy more than 42 days after the pleural 
intervention, or using a radiotherapy ﬁ eld size less than 
that stipulated in the protocol.
Full details of the analysis of the secondary outcomes 
can be found in the statistical analysis plan.18 Where 
numbers allowed, the analyses were adjusted for the 
minimisation factors and the parameter measured at 
baseline (if the data were continuous). For longitudinal 
data, an area under the curve was calculated using the 
trapezium rule, and this was divided by the duration of 
follow-up to give a summary score, which was used for 
the analysis. Time-to-event data were analysed using the 
Kaplan-Meier method. Hazard ratios and 95% CIs were 
calculated by ﬁ tting a Cox model. Safety outcomes were 
assessed in all patients who received radiotherapy. Safety, 
toxicity, and patient experience outcomes were reported 
descriptively. Only serious adverse events related to a 
PTM or radiotherapy were reported, as per the original 
trial protocol. The incremental cost-eﬀ ectiveness ratio 
was calculated as the diﬀ erence in mean costs (immediate 
radiotherapy minus deferred radiotherapy) divided by 
the diﬀ erence in mean quality-adjusted life-years (QALYs; 
immediate radiotherapy minus deferred radiotherapy).
Stata (version 14) was used for statistical analyses. 
This study was registered with ISRCTN, number 
ISRCTN72767336.
Role of the funding source
The funders had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between Dec 23, 2011, and Aug 4, 2014, we assessed 
457 patients for eligibility, and 203 patients were 
subsequently randomised and included in the primary 
analysis (ﬁ gure 1). Baseline characteristics between the 
two groups were well matched, with no substantial 
diﬀ erences identiﬁ ed between the groups (table 1). 
The number of patients followed up until death or for 
12 months was 97 (95%) in the immediate radiotherapy 
group (three [3%] did not attend and two [2%] withdrew) 
and 94 (93%) in the delayed radiotherapy group (six [6%] 
did not attend and one [1%] withdrew). The median 
duration of follow-up was 343 days (IQR 201–370) in the 
immediate radiotherapy group and 349 days (212–370) in 
the deferred radiotherapy group. In the overall study 
population, 91 (45%) patients were randomised following 
a video-assisted thoracoscopic surgery, 74 (36%) after a 
local anaesthetic thoracoscopy, 25 (12%) following an 
indwelling pleural catheter insertion, nine (4%) after a 
thoracotomy, and three (1%) following large-bore chest 
drain insertion (table 1). One patient in the immediate 
radiotherapy group was randomised in error following 
a CT-guided pleural biopsy but was included in the 
primary analysis on an intention-to-treat basis.
99 of 102 patients in the immediate radiotherapy group 
received the radiotherapy as assigned (three deteriorated 
clinically between randomisation and treatment 
precluding irradiation; ﬁ gure 1). All 99 patients received 
radiotherapy of 21 Gy in three fractions, delivered using 
6–18 meV electrons (85 [87%]), Kv photons (11 [11%]), 
Mv photons (two [2%]), or unknown (one [1%]; appendix). 
97 (98%) patients were treated with a single direct beam, 
one patient was treated with parallel pair tangents, and 
one had missing data. 60 (61%) had bolus administered, 
38 (38%) had no bolus, and one had missing data. 
Eight patients had an immediate radiotherapy ﬁ eld size 
Figure 1: Trial proﬁ le
*One patient randomised after CT-guided biopsy and more than 35 days after the pleural intervention; 
three patients randomised more than 35 days after the pleural intervention.
102 allocated to immediate radiotherapy 
203 enrolled and randomised
457 patients assessed for eligibility
254 not randomised
 73 declined
 154 did not meet eligibility criteria
  25 had ineligible chest wall procedure
  33 mesothelioma not confirmed
  47 had procedure >35 days prior to recruitment
  17 had expected survival <4 months
  3 unable to consent or comply with protocol
  8 had previous radiotherapy with unacceptable 
  overlap of treatment field
  5 had palpable chest wall nodule at initial trial visit
  16 other reasons
 9 clinician’s decision
 18 other reasons or no reason given
101 allocated to deferred radiotherapy 
102 included in primary analysis
 (intention-to-treat population)
3 clinical deterioration before 
 treatment
101 included in primary analysis
 (intention-to-treat population)
84 in per-protocol analysis 99 in per-protocol analysis 
4 inappropriate randomisation* 
8 field size smaller than stipulated
3 received first fraction >42 days 
 after pleural intervention
2 randomised >35 days after
pleural intervention
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smaller than that stipulated in the protocol and three had 
the ﬁ rst fraction of immediate radiotherapy given 
more than 42 days after the randomised procedure 
(appendix).
Nine of 16 patients in the deferred radiotherapy group 
who developed a PTM received radiotherapy according 
to the protocol (appendix). Two patients were too unwell 
 Immediate 
radiotherapy 
(n=102)
Deferred 
radiotherapy 
(n=101)
Sex
Male 91 (89%) 90 (89%)
Female 11 (11%) 11 (11%)
Age (years) 70 (66–76) 70 (66–77)
Time from diagnosis to 
randomisation (days)
21 (14–25) 20 (13–27)
Mean time from pleural intervention 
to randomisation (days)
22·8 (7·7) 22·2 (8·1)
WHO performance score
0 29 (28%) 34 (34%)
1 61 (60%) 53 (52%)
2 9 (9%) 11 (11%)
3 3 (3%) 3 (3%)
Karnofsky performance score 90 (80–90)* 80 (80–90)
Body-mass index 26·2 (4·3)† 26·5 (3·3)†
Extrathoracic spread on imaging
Yes 4 (4%) 2 (2%)
No 81 (79%) 80 (79%)
Unknown 17 (17%) 19 (19%)
Histological subtype
Epithelioid only 71 (70%) 71 (70%)
Sarcomatoid 8 (8%) 8 (8%)
Biphasic (mixed) 19 (19%) 18 (18%)
Desmoplastic 4 (4%) 0
Other 0 4 (4%)
Basis for diagnosis
Pleural ﬂ uid cytology 0 3 (3%)
Pleural biopsy 102 (100%) 98 (97%)
Side of disease
Left 32 (31%) 40 (40%)
Right 69 (68%) 61 (60%)
Bilateral 1 (1%) 0
Smoking status
Current 6 (6%) 7 (7%)
Former 59 (58%) 54 (53%)
Never 37 (36%) 40 (40%)
Comorbidities
Respiratory disease 5 (5%) 11 (11%)
Cardiac disease 9 (9%) 12 (12%)
Chronic renal failure 3 (3%) 3 (3%)
Diabetes 15 (15%) 14 (14%)
Steroid use 6 (6%) 5 (5%)
Symptomatic pleural eﬀ usion at 
presentation
91 (89%) 90 (89%)
Chest pain at presentation 36 (35%) 37 (37%)
Previous pleurodesis 54 (53%) 68 (67%)
(Table 1 continues in next column)
 Immediate 
radiotherapy 
(n=102)
Deferred 
radiotherapy 
(n=101)
(Continued from previous column)
Type of pleural intervention
Large-bore chest drain insertion 1 (1%) 2 (2%)
Local anaesthetic thoracoscopy 38 (37%) 36 (36%)
Thoracotomy 3 (3%) 6 (6%)
Video-assisted thoracoscopic 
surgery
45 (44%) 46 (46%)
Indwelling pleural catheter 
insertion
14 (14%) 11 (11%)
Other 1 (1%)‡ 0
Number of pleural puncture sites
1 69 (68%) 68 (67%)
2 27 (26%) 26 (26%)
≥3 6 (6%) 6 (6%)
Unknown 0 1 (1%)
Previous chemotherapy received 
for mesothelioma
3 (3%) 6 (6%)
Previous radiotherapy received for 
mesothelioma
1 (1%) 2 (2%)
Oral morphine-equivalent dose (mg) 0 (0–0) 0 (0–0)
Quality of life§ 
QLQ-C30 global health status 
subscale
66·7 (50·0–83·3), 
n=98
66·7 (50·0–83·3), 
n=96
QLQ-C30 physical functioning 
subscale
80·0 (53·3–93·3), 
n=98
76·7 (60·0–86·7), 
n=96
QLQ-C30 pain subscale 16·7 (0·0–33·3), 
n=98
16·7 (0·0–33·3), 
n=97
EQ-5D utility score 0·79 
(0·69–0·85), 
n=100
0·78 
(0·62–0·85), 
n=98
Chest pain (visual analogue scale scores)¶
On average how much chest pain 
have you felt today? 
5·0 (0·0–17·0) 4·0 (0·5–18·5)
How much has chest pain 
bothered you today? 
3·3 (0·0–13·7) 3·0 (0·0–14·8)
On average how much pain have 
you felt today from the site of your 
previous chest wall procedure?
3·0 (0·0–10·0) 2·8 (0·5–15·8)
How much has pain from the site 
of your previous chest wall 
procedure bothered you today?
1·5 (0·0–8·0) 3·0 (0·5–15·0)
Data are n (%), median (IQR), or mean (SD). QLQ-C30=European Organization for 
Research and Treatment of Cancer Quality-of-Life Questionnaire—Core 30. 
EQ-5D=EuroQoL-5D. *n=101; one patient had missing data for Karnofsky 
performance score at baseline. †n=98 in the immediate radiotherapy group and 
n=97 in the delayed radiotherapy group because the data were not recorded at 
baseline for the remaining patients. ‡CT-guided biopsy; this patient was 
randomised in error. §Quality-of-life scores were derived from two separate 
questionnaries (QLQ-C30 and EQ-5D), and not all patients completed both at 
baseline; not all patients completed individual questions necessary to calculate a 
certain QLQ-C30 subscale. ¶n=97 in the delayed radiotherapy group because the 
remaining patients did not complete baseline visual analogue scale scores. 
Table 1: Baseline characteristics
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for radiotherapy when the PTM was diagnosed, one 
patient declined radiotherapy, two patients had a PTM 
diagnosed at their ﬁ nal trial visit and therefore completed 
trial follow-up before radiotherapy could be given, and 
two had missing data.
The other treatments received by patients during their 
trial follow-up are listed in the appendix. 119 (59%) of 
203 patients received ﬁ rst-line pemetrexed–platinum 
chemotherapy after trial entry, and 11 (5%) of 203 had 
second-line chemotherapy (appendix).
The primary, intention-to-treat analysis revealed no 
signiﬁ cant diﬀ erence between the proportion of patients 
who developed PTMs in the immediate and deferred 
radiotherapy groups (nine [8·8%] of 102 patients vs 
16 [15·8%] of 101 patients respectively; OR 0·51 [95% CI 
0·19–1·32]; p=0·14; table 2). The results of the predeﬁ ned 
subgroups are shown in table 3.
183 patients were included in the per-protocol analysis 
(ﬁ gure 1). Reasons for exclusions were: six patients 
were inappropriately randomised (one patient in the 
Immediate 
radiotherapy
Deferred 
radiotherapy
Odds ratio 
(95% CI)
p value
Number of patients developing a PTM
Intention-to-treat analysis 9/102 (9%) 16/101 (16%) 0·51 (0·19–1·32) 0·14
Per-protocol analysis 5/84 (6%) 16/99 (16%) 0·33 (0·09–1·00) 0·037
Number of patients developing a painful PTM 2/102 (2%) 6/101 (6%) 0·32 (0·03–1·84) 0·17
Time to development of PTM from randomisation (days) 179 (126–221) 224 (136–285) NA* 0·34
Summary chest pain visual analogue scale score from diagnosis of PTM to 12 months after randomisation†
On average how much chest pain have you felt today? 26·2 (10·3–53·7) 18·8 (5·5–32·2) NA* 0·74
On average how much has chest pain bothered you today? 24·5 (9·7–51·9) 16·4 (4·4–49·7) NA* 0·92
On average how much pain have you felt today from the site of your previous 
chest wall procedure?
9·9 (7·1–28·3) 15·4 (8·2–42·4) NA* 0·63
On average how much has pain from the site of your previous chest wall 
procedure bothered you today?
12·3 (7·0–28·5) 13·0 (6·4–42·9) NA* 0·77
Summary morphine-equivalent dose from diagnosis of PTM to 12 months after 
randomisation‡
12·6 (1·4–33·5) 16·0 (5·0–45·0) NA* 0·53
Number of patients developing a chest wall nodule anywhere on the ipsilateral 
hemithorax
13/102 (13%) 16/101 (16%) 0·78 (0·32–1·84) 0·55
Data are n/N (%) or median (IQR), unless otherwise speciﬁ ed. PTM=procedure-tract metastasis. NA=not applicable. *Because of the small number of patients, the groups 
were compared by Mann Whitney U tests; therefore, no treatment eﬀ ect was obtained. †n=8 in the immediate radiotherapy group and n=9 in the deferred radiotherapy 
group, because there were insuﬃ  cient data after PTM development to calculate an area under the curve for the remaining patients. ‡n=7 in the immediate radiotherapy 
group; n=10 in the deferred radiotherapy group.
Table 2: PTM development
Median time to 
development of PTM from 
randomisation (days)
Number of patients developing a PTM
Immediate 
radiotherapy
Deferred 
radiotherapy
Odds ratio (95% CI) p value
Pleural intervention procedure type
Large-bore chest drain insertion (≥20 Fr) NA 0/1 (0%) 0/2 (0%) NA NA
Local anaesthetic thoracoscopy 187·5 (140–265) 4/38 (11%) 4/36 (11%) 0·94 (0·16–5·51) 1·00
Thoracic surgery (thoracotomy or video-assisted 
thoracic surgery)
221 (146–290) 4/48 (8%) 9/52 (17%) 0·43 (0·09–1·71) 0·24
Indwelling pleural catheter insertion 136·5 (80·5–206·5) 1/14 (7%) 3/11 (27%) 0·21 (0·00–3·27) 0·29
Tumour subtype
Epithelioid only 221 (158–285) 6/71 (8%) 15/72 (21%) 0·35 (0·11–1·04) 0·057
Other 32·5 (23·0–94·5) 3/31 (10%) 1/29 (3%) 3 (0·22–163) 0·61
Patients followed-up for ≥6 months 221 (158–285) 8/80 (10%) 13/76 (17%) 0·54 (0·18–1·51) 0·24
Chemotherapy after trial entry
Yes 221 (126–266) 7/56 (13%) 8/64 (13%) 1·00 (0·29–3·41) 1·00
No 163 (101–304) 2/46 (4%) 8/37 (22%) 0·16 (0·02–0·93) 0·021
Data are median (IQR), or n/N (%), unless otherwise speciﬁ ed. PTM=procedure-tract metastasis. NA=not available.
Table 3: Subgroup analyses for the primary outcome 
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immediate radiotherapy group had CT-guided biopsy 
and was randomised more than 35 days after the pleural 
intervention, and ﬁ ve patients [three in the immediate 
radiotherapy group and two in the deferred radiotherapy 
group] were randomised more than 35 days after the 
pleural intervention); three patients did not have the 
assigned immediate radiotherapy because of clinical 
deterioration; eight had an immediate radiotherapy ﬁ eld 
size smaller than that stipulated in the protocol; and 
three had the ﬁ rst fraction of immediate radiotherapy 
given more than 42 days after their pleural intervention. 
Four patients in the immediate radiotherapy group who 
developed a PTM were excluded from the per-protocol 
analysis (in three cases, the ﬁ eld size was too small and 
one patient was randomised 36 days after the pleural 
intervention; appendix).
The secondary per-protocol analysis showed that PTM 
incidence was signiﬁ cantly lower in the immediate 
radiotherapy group than in the deferred radiotherapy 
group (table 2). Most PTMs were identiﬁ ed more than 
6 months from the pleural intervention procedure 
after which the patients were randomised (ﬁ gure 2). 
No diﬀ erence was seen in the time to development of 
PTM from randomisation between the treatment 
groups (p=0·34; table 2). Nine patients in the immediate 
radiotherapy group had PTMs (mean size of PTMs at 
diagnosis 3·1 cm [SD 2·9]), and 16 patients in the 
deferred radiotherapy group had PTMs (4·6 cm [2·6]; 
p=0·083). There were insuﬃ  cient data for a formal 
analysis of how the size of the nodules changed over 
time. The minimum distance between the procedure 
site and the edge of the PTM was longer in the 
immediate radiotherapy group (mean 4·6 cm [SD 2·6]) 
than in the deferred radiotherapy group (1·3 cm [1·8]; 
p=0·0049). Four of the nine patients who developed a 
PTM in the immediate radiotherapy group did so more 
than 2 cm from the immediate radiotherapy ﬁ eld. 
In addition to the 25 patients who developed a PTM 
within 7 cm of the site of pleural intervention procedure 
(meeting the primary endpoint criteria), a further 
four patients in the immediate radiotherapy group 
developed an ipsilateral chest wall nodule more than 
7 cm from the procedure site. No signiﬁ cant diﬀ erence 
was identiﬁ ed in the total number of patients developing 
a chest wall nodule anywhere on the ipsilateral 
hemithorax (table 2). 
No diﬀ erence was reported in chest pain, as assessed 
by visual analogue scale scores, in the two treatment 
groups at baseline and during trial follow-up (tables 1, 4). 
Additionally, no diﬀ erence was seen between the groups 
in terms of analgesia use, as measured by oral morphine-
equivalent doses at baseline, or summary scores during 
trial follow-up (tables 1, 4).
Of the 25 patients who developed PTM, no 
diﬀ erences were identiﬁ ed in terms of the summary 
visual analogue scale scores or morphine-equivalent 
doses between the treatment groups (table 2). 
The numbers were too small for a formal survival 
analysis from the time of PTM diagnosis to death. 
Results of the chest wall lump questionnaire, 
completed by patients who developed PTMs, also 
revealed no diﬀ erences in terms of patient experience 
between the treatment groups (appendix). Only 
eight patients (4% of 203 patients in the study; 32% of 
25 patients who developed a PTM) had PTMs that 
were tender at the time of identiﬁ cation (table 2). 
The number needed to treat to prevent one painful 
PTM was 25·1. The proportion of PTMs that were 
painful was similar in the immediate radiotherapy 
group (two [22%] of nine) and in the deferred 
radiotherapy group (six [38%] of 16; odds ratio 0·48 
[95% CI 0·04–3·94]; p=0·66; table 2).
Quality of life of the two groups—as measured by the 
global health status, fatigue, pain, and appetite loss 
subscales of the QLQ-C30—was similar at baseline and 
during trial follow-up, both in terms of interval change 
from baseline to 1 month and in terms of the overall 
summary score during trial follow-up (tables 1, 4). 
No diﬀ erence in quality of life was identiﬁ ed at baseline 
or during trial follow-up by the summary scores derived 
from the EQ-5D utility scores (table 4).
Median overall survival from randomisation was 
357 days (95% CI not estimable) in the immediate 
radiotherapy group and 365 days (not estimable) in the 
deferred radiotherapy group (ﬁ gure 3).
Immediate radiotherapy was generally well tolerated 
both in terms of side-eﬀ ects and in terms of patient 
experience (table 5; appendix). There were no 
treatment-related deaths or withdrawals. Only one 
serious adverse event related to a PTM or radiotherapy 
was reported: one patient in the immediate 
radiotherapy group developed a painful PTM within 
the radiotherapy ﬁ eld that required hospital admission 
for symptom control 8 months after randomisation 
(table 5). Among patients who received immediate 
radiotherapy, common adverse events were grade 1 
Figure 2: Time to development of PTM, by treatment group and histological subtype
PTM=procedure-tract metastasis. 
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skin toxicity and tiredness or lethargy within 3 months 
of receiving radiotherapy (table 5). The relative 
incidence of indwelling pleural catheter complications 
was similar in the two groups (appendix). Of 93 patients 
in the immediate radiotherapy group who completed 
the patient experience questionnaire, 26 (28%) patients 
said that they found attending radiotherapy at least a 
little inconvenient, 27 (29%) reported that radiotherapy 
interfered with their usual activities, and 27 (29%) 
said that radiotherapy aﬀ ected their quality of life 
(appendix). However, 84 (90%) patients said that they 
found attending radiotherapy at least a little reassuring 
(appendix). Five patients in the deferred radiotherapy 
group completed the post-radiotherapy questionnaire, 
and their experiences were comparable to those of the 
immediate radiotherapy group (appendix).
No signiﬁ cant or meaningful diﬀ erences were seen in 
mean total cost (£5475 [SD 703] in the immediate 
radiotherapy group vs £5473 [773] in the deferred 
radiotherapy group) or in mean QALYs (0·504 [SD 0·03] 
vs 0·516 [0·03]). The point estimate of the incremental 
cost-eﬀ ectiveness ratio for immediate radiotherapy 
compared with deferred radiotherapy was –£85·19 per 
QALY. 
Discussion
Results from the SMART trial showed that, for patients 
with malignant pleural mesothelioma, treatment with 
prophylactic radiotherapy after large-bore pleural 
interventions does not reduce the incidence of PTM and 
confers no beneﬁ ts in terms of symptom control, 
analgesia use, survival, or quality of life. To our 
knowledge, the SMART trial is the largest trial 
investigating this research question and the ﬁ rst to fully 
Number included in 
analysis
Median number of 
timepoints used to 
generate summary score 
Summary score Diﬀ erence in means* p value
Immediate 
radiotherapy
Deferred 
radiotherapy
Immediate 
radiotherapy
Deferred 
radiotherapy
Immediate 
radiotherapy
Deferred 
radiotherapy
Summary visual analogue scale score
On average how much chest pain have you 
felt today?
93 96 10 (6 to 12) 10 (5 to 12) 12·0 (3·3 to 23·3) 9·0 (2·9 to 27·0) 0·6 (–3·3 to 4·6) 0·75
On average how much has chest pain 
bothered you today?
93 96 10 (6 to 12) 10 (5 to 12) 9·1 (2·7 to 20·6) 7·8 (2·6 to 24·1) 0·8 (–3·1 to 4·6) 0·70
On average how much pain have you felt 
today from the site of your previous chest 
wall procedure?
93 95 10 (6 to 12) 10 (5 to 12) 6·9 (2·4 to 16·4) 5·3 (2·2 to 16·8) 1·0 (–2·3 to 4·2) 0·56
On average how much has pain from the 
site of your previous chest wall procedure 
bothered you today?
93 95 10 (6 to 12) 10 (5 to 12) 5·5 (1·2 to 15·1) 5·5 (2·1 to 17·7) 0·5 (–2·7 to 3·6) 0·76
QLQ-C30 summary score
Global health status 91 92 5 (3 to 6) 5 (3 to 6) 59·6 (45·8 to 70·8) 61·6 (43·1 to 74·9) –1·2 (–5·2 to 2·8) 0·55
Physical functioning 91 92 5 (3 to 6) 5 (3 to 6) 71·0 (54·8 to 83·7) 70·3 (49·5 to 84·4) –0·1 (–3·1 to 2·9) 0·94
Pain 91 93 5 (3 to 6) 5 (3 to 6) 22·8 (8·7 to 35·1) 16·7 (6·7 to 35·9) 1·3 (–3·1 to 5·6) 0·57
EQ-5D summary score (time trade-oﬀ  scores) 94 95 5 (3 to 6) 5 (3 to 6) 0·72 (0·56 to 0·83) 0·72 (0·58 to 0·82) –0·02 (–0·06 to 0·02) 0·38
Mean change in QLQ-C30 scores from 
randomisation to 1 month
Global health status 83 87 NA NA 6·2 (21·0) 5·3 (24·3) 0·8 (–5·5 to 7·0) 0·81
Physical functioning 83 88 NA NA 5·7 (12·6) 4·5 (12·7) 0·9 (2·8 to –4·7) 0·62
Fatigue 83 88 NA NA –3·2 (23·1) –2·6 (20·8) 0·0 (–5·5 to 5·5) 1·00
Pain 84 88 NA NA –0·6 (22·2) –3·2 (23·0) 2·8 (–3·3 to 9·0) 0·36
Appetite loss 83 88 NA NA 2·0 (30·1) –2·7 (32·1) 1·9 (–5·5 to 9·2) 0·62
Morphine-equivalent dose summary score 102 101 5 (4 to 6) 5 (4 to 6) 2·7 (0 to 17·3) 1·9 (0 to 10·5) NA† 0·50
Data are n, median (IQR), or mean (SD). QLQ-C30=European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire—Core 30. EQ-5D=EuroQoL-5D. NA=not applicable. *Adjusted diﬀ erence 
in mean summary scores (immediate radiotherapy group – deferred radiotherapy group). †Non-parametric comparison was used because of skewed data, so no diﬀ erence in means was generated. 
Table 4: Visual analogue scale scores, quality-of-life variables, and morphine-equivalent doses
Figure 3: Overall survival from randomisation
HR=hazard ratio.
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assess the important patient-centred outcomes of pain 
and quality of life.
The overall incidence of PTM in this study was low, 
with 93 (91%) patients in the immediate radiotherapy 
group and 85 (84%) in the deferred radiotherapy 
group not developing a PTM during trial follow-up. 
No signiﬁ cant diﬀ erence in the incidence of PTM was 
seen between the treatment groups, despite our study 
being the largest so far and having recruited more 
patients than the three previous randomised controlled 
trials5–7 combined. This ﬁ nding, along with the absence 
of any patient-centred, symptomatic beneﬁ t conferred 
by immediate radiotherapy, suggests that even if 
prophylactic radiotherapy was mildly eﬃ  cacious if 
given to a large enough number of patients (number 
needed to treat to prevent a painful PTM 25·1), the 
patient-derived beneﬁ t would be no better than careful 
clinical follow-up and treatment should a nodule 
develop.
Some potentially interesting ﬁ ndings from the 
secondary subgroup analyses might warrant further 
investigation. The secondary per-protocol analysis, 
which excluded patients with serious protocol 
deviations, showed a diﬀ erence in PTM incidence 
between the treatment groups. This ﬁ nding highlights 
the possibility that if adequate radiotherapy is given 
according to our protocol, the rate of PTM might be 
reduced, but the clinical relevance of this and whether 
reliable delivery of such a protocol in real-world settings 
is feasible (in view of the number of protocol deviations 
in this trial) are unclear. Importantly, however, the lack 
of diﬀ erence between the treatment groups in terms of 
any of the patient-centred outcomes (including pain 
and quality of life) and the low rate of occurrence of 
symptomatic nodules suggest that patients were not 
disadvantaged by an active surveillance strategy and 
prompt administration of radiotherapy in the event of a 
nodule being detected.
Two potential signals were identiﬁ ed in the predeﬁ ned 
subgroup analyses. The ﬁ rst was a suggestion that 
immediate radiotherapy was eﬀ ective in reducing PTMs 
in the subgroup of patients with epithelioid-only 
histological tumour subtypes, which is likely to reﬂ ect the 
improved survival of this subgroup and hence an 
increased duration of potential beneﬁ t from the treatment. 
Second, in the subgroup of patients who did not receive 
chemotherapy after trial enrolment, those who received 
immediate radiotherapy had a lower PTM rate than had 
those in the deferred radiotherapy group. This ﬁ nding 
suggests potential beneﬁ ts in terms of prevention of 
locoregional recurrence from chemo therapy in addition 
to the well established systemic beneﬁ ts. It might also 
explain the results of a large retrospective case series20 
supporting a role for prophylactic irradiation of tracts, in 
which the proportion of patients receiving chemotherapy 
was signiﬁ cantly lower in patients who did not receive 
immediate radiotherapy than in those who did. 
The results of the PIT study,21 a randomised controlled 
trial assessing prophylactic irradiation of tracts in 
mesothelioma, which is in its follow-up period at present, 
are awaited with interest. These results will allow 
combination of the available data from published studies 
to gain further insights into the role of prophylactic 
radiotherapy in mesothelioma, particularly in these 
potentially relevant subgroups identiﬁ ed in our study.
Overall, the rate of symptomatic PTM in this study was 
low. Eight (4%) of 203 patients in the study had a tender 
nodule at presentation, and eight (32%) of the 25 patients 
who developed a PTM had a tender nodule, which is 
similar to the proportions in a previous study.6 
No diﬀ erence was identiﬁ ed between the treatment 
groups, again suggesting that prophylactic radiotherapy 
does not aﬀ ect the development of symptoms from 
PTMs in this population. Only one patient, who was in 
the immediate radiotherapy group, required hospital 
admission for symptom control relating to a PTM.
Within 3 months of 
receiving radiotherapy
>3 months after receiving 
radiotherapy
Immediate 
radiotherapy 
(n=92)*
Deferred 
radiotherapy 
(n=5)†
Immediate 
radiotherapy 
(n=78)‡
Deferred 
radiotherapy 
(n=1)§
Skin toxicity¶
Grade 0 38 (41%) 3 (60%) 37 (47%) 1 (100%)
Grade 1 50 (54%) 2 (40%) 40 (52%) 0
Grade 2 4 (4%) 0 1 (1%) 0
Grade 3 0 0 0 0
Grade 4 0 0 0 0
Subcutaneous tissue toxicity¶ ||
Grade 0 ¨ ¨ 76 (97%) 1 (100%)
Grade 1 ¨ ¨ 2 (3%) 0
Grade 2 ¨ ¨ 0 0
Grade 3 ¨ ¨ 0 0
Grade 4 ¨ ¨ 0 0
Grade 5 ¨ ¨ 0 0
Nausea 10 (11%) 0 3 (4%) 0
Tiredness 
or 
lethargy 
36 (39%) 2 (40%) 18 (23%) 0
Loss of 
appetite 
1 (1%) 0 0 0
Pain 2 (2%) 0 0 0
Data are n (%). Adverse events in this table relate to either immediate 
radiotherapy or deferred radiotherapy (given to treat a PTM). 
PTM=procedure-tract metastasis. *Ten of 102 patients were excluded (ﬁ ve were 
too unwell or died before follow-up, one declined follow up, and four had missing 
data). †Four of nine patients were excluded (two died before follow-up and 
two had missing data). ‡24 patients were excluded (21 were too unwell or died 
before follow-up, one declined follow-up, and two had missing data). 
§Eight patients were excluded (four died before follow-up, three had missing 
data, and one developed PTM too late in the follow-up period to identify late 
toxicity. ¶Radiation Therapy Oncology Group grading system. ||Subcutaneous 
tissue toxicity is not in early assessments of the grading system. 
Table 5: Adverse events related to radiotherapy, according to the trial 
protocol 
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Complication rates of indwelling pleural catheters did 
not seem to be aﬀ ected by radiotherapy, suggesting that 
these catheters are a safe treatment in this context, 
although again we did not identify any beneﬁ ts of 
delivering prophylactic radiotherapy in this subgroup of 
patients. However, it is reassuring that the catheters 
themselves were not adversely aﬀ ected by radiotherapy 
treatment, suggesting that palliative radiotherapy could 
be safely administered to the region of an indwelling 
pleural catheter if necessary.
Immediate prophylactic radiotherapy in this population 
was not cost-eﬀ ective, compared with deferred radio-
therapy for symptomatic treatment. If we assume that 
publicly funded health-care systems (eg, NHS in the UK) 
are willing to pay £30 000 for incremental health gains 
(ie, an additional QALY), then immediate radiotherapy 
compared with deferred radiotherapy in patients with 
malignant mesothelioma following large-bore chest 
procedure is estimated to be cost-eﬀ ective only 40% of 
the time (data to be published in full in a separate paper). 
However, radiotherapy was generally well tolerated and 
the frequency of skin toxicity was low, despite the larger 
ﬁ eld size used in this trial than in previous studies. Most 
patients who received immediate radiotherapy found it 
reassuring, although they did report some inconvenience 
associated with attendance for the radiotherapy sessions.
This study has several strengths. To our knowledge, it 
is the largest study so far and was suitably powered 
to investigate this important research question in 
mesothelioma. It was designed to be a pragmatic trial to 
assess prophylactic radiotherapy in mesothelioma in a 
real-world setting. We assessed several important 
patient-centred secondary endpoints that have not been 
previously studied. We followed up patients until death 
or for 12 months, ensuring that all PTMs were carefully 
identiﬁ ed by independent examinations by two clinicians 
at each clinic visit, which is essential in view of the fact 
that many PTMs were identiﬁ ed in the later months of 
trial follow-up. The SMART trial is also the ﬁ rst to 
investigate the role of prophylactic radiotherapy since 
eﬀ ective systemic chemotherapy has become available 
for mesothelioma and to assess its role in the context of 
indwelling pleural catheter use.
Potential limitations include the absence of blinding 
of participants or assessors, which would not have been 
possible within the trial budget. The failure rate of 
screening was high, predominantly because patients did 
not meet the trial’s eligibility criteria, which were all 
deemed important factors to ensure that the results 
were valid and robust. The number of protocol 
deviations, speciﬁ cally those related to the delivery of 
immediate radiotherapy, could also be viewed as a 
limitation of this study. However, these deviations in 
compliance with the protocol are likely to reﬂ ect 
real-world variation in practice and might be even more 
substantial outside the trial setting. The ﬁ eld size of 
radiotherapy was selected on the basis of results from 
previous studies and what was deemed reasonable to 
minimise radiotherapy toxicity; however, it could be 
argued that an even larger, more superiorly conﬁ gured 
ﬁ eld might have been more eﬀ ective.22 However, 
whether these more distant nodules represent true 
PTMs or local tumour invasion unrelated to the previous 
pleural interventions is impossible to distinguish, and 
selection of a practical and realistic radiotherapy 
protocol was deemed vital for the purposes of this study 
to make the results universally applicable. Few patients 
in the SMART trial had undergone large surgical 
procedures (eg, thoracotomies), and hence it is not 
possible to give a speciﬁ c recommendation regarding 
prophylactic radio therapy in this group of patients.
Overall, our data do not support the use of routine 
prophylactic radiotherapy after large-bore pleural 
interventions for all patients with mesothelioma. 
Although some suggestion of beneﬁ t was identiﬁ ed in 
speciﬁ c patient subgroups, the applicability of these 
ﬁ ndings is limited by the small numbers. Therefore, 
more data from randomised controlled trials are needed 
before the use of prophylactic radiotherapy in these 
contexts can be fully established. No signiﬁ cant diﬀ erence 
was identiﬁ ed in terms of PTM rate, chest pain, quality of 
life, analgesia requirements, or survival, and immediate 
radiotherapy was not cost-eﬀ ective. Patients were not 
symptomatically disadvantaged by careful clinical 
follow-up and later radiotherapy should a PTM develop. 
Our ﬁ ndings do not support routine use of prophylactic 
irradiation of tracts in mesothelioma, provided that the 
patient receives regular clinical follow-up to ensure 
symptoms are identiﬁ ed and treated early.
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